Challenges in Chronic Pain Management — An Update
COX2s and Traditional NSAIDs: Risks and Benefits in Pain Management
Please read through the following information and click continue.

Release Date: February 14, 2007
Expiration Date: February 14, 2010

Target Audience
Pharmacists who care for patients needing pain management.

Statement of Need
There are anecdotal reports about the COX-2 inhibitors of improved efficacy over the traditional NSAIDs. This program will help the practitioner identify those patients with specific risk factors, in whom the risks would outweigh potential benefits, and properly educate those for whom COX-2 use is still an option.

Educational Objectives
Upon completion of this program, participants should be able to improve their patient care by being able to:

1. Differentiate between the COX-1 and COX-2 enzymes and the effects of their inhibition by NSAIDs and COX-2 drugs.
2. Discuss the methods, results, and conclusions drawn from the VIGOR and CLASS trials.
3. Evaluate patient risk factors to properly select COX-2 selective NSAID or traditional NSAID for chronic pain.
4. Use the FDA Subcommittees recommendations for chronic use of NSAIDs for pain to evaluate appropriateness of therapy.

Faculty Information
Kenneth C. Jackson, II, PharmD
Clinical Associate Professor of Pharmacotherapy
Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center
Clinical Pharmacist —Pain & Palliative Care
University of Utah Health Sciences Center
Salt Lake City, Utah

Accreditation
Pharmacists

The National Community Pharmacists Association (NCPA®) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program will provide 2.0 contact hours (0.2 CEUs) of credit under the program number 207-999-07-064-H01-P.
.



Instructions
To receive credit for this program, you must:

• Review the full content of the program and reflect on its teaching.
• Successfully complete the post-test with a minimum grade of 70% or higher.
• You will have two (2) opportunities to successfully complete the program.

Your statement of credit will be issued immediately upon successful completion and submission of the post-test and evaluation.

Fee
There is no fee for this activity.

NCPA does not have a relevant financial relationship with any commercial interests related directly or indirectly to the content of this educational activity.

Kenneth C. Jackson, II, PharmD has disclosed that he has received grant/research support for Medgenex, Inc., Pfizer, Inc., and Novartis. He is also on the speakers' bureau for HospiScript Services, LLC.

It is the policy of the accreditors to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing medical education activities.


Unlabeled Use Disclosure
The author and sponsor of this continuing medical education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g. their administration, dosages, contraindications, adverse reactions, interactions, special warning, precautions) and drug delivery systems is subject to change; however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery system.

The faculty has indicated that there will be no discussion of unlabeled/unapproved use of products during the presentation.

Commercial Support

This program is supported by an educational grant from Pfizer Inc.

Software Requirements

PC Windows 2000 Internet Explorer 5.5 or Firefox *Adobe Acrobat Reader	MAC Mac OS 10.2.8 Safari *Adobe Acrobat Reader
*REQUIRED TO VIEW PRINTABLE VERSION OF CE LESSON

Continue